October 28, 2016 (Shareholders Foundation) - An investigation on behalf of investors of Juniper Pharmaceuticals Inc (NASDAQ:JNP) shares over potential securities laws violations by Juniper Pharmaceuticals and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Juniper Pharmaceuticals Inc (NASDAQ:JNP) concerning whether a series of statements by Juniper Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Juniper Pharmaceuticals Inc reported that its annual Total Revenue rose from $32.46 million in 2014 to $37.56 million in 2015 while its Net Income of $3.39 million in 2014 declined to a Net loss of $2.13 million.

On October 24, 2016, Juniper Pharmaceuticals Inc stated in a regulatory filing that its annual statements for 2013 to 2015 as well as its statements for the quarters ended March 31 and June 30, 2016, should no longer be relied upon. Juniper Pharmaceuticals Inc will have to restate its financial statements due to revenue-recognition errors related to a supply agreement with an affiliate of Germany's Merck KGaA.

Shares of Juniper Pharmaceuticals Inc (NASDAQ:JNP) closed on October 28, 2016 at $5.65 per share.